unstimulated peripheral blood contains less than one tenth the number of progenitors as marrow, the total number present in mobilized leukapheresis harvests and infused We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgto reconstitute hematopoiesis may exceed marrow by several fold.
Each patient had 7 ؋ 10 8 mononuclear cells (MNC) per kg collected. G-CSF was administered post-PBSC
after the administration of hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) 6, 10, 11 alone, or in combination with chemofour (15%) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients therapy.
12- 16 We report our experience regarding the effectiveness of revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r G-CSF-mobilized PBSC as a source of progenitors in patients with advanced lymphomas and breast or ovarian = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34 + cancer who received high-dose/myeloablative conditioning regimens. We have examined the relationship between stem cells had consistently better hematologic parameters at all times examined. At 180 days post-transplant, the cell yield and both early engraftment and late hematopoietic reconstitution, and the clinical factors associated with the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 ؋ 10
Mobilization regimens and leukapheresis
PHA-LCM (Stem Cell Technologies, Vancouver, BC, Canada), were plated in triplicate into 1 ml tissue culture Patients had PBSC collected in one of two ways. They were plates and incubated in humidified 5% CO 2 at 37°C for selected to receive G-CSF for 5 consecutive days with leu-14 days. The plates were scored for colony-forming unit kapheresis commencing on day 6, or they received chemogranulocyte and macrophage (CFU-GM), burst-forming therapy followed 24-48 h later by daily G-CSF. G-CSF unit erythroid (BFU-E) and colony-forming unit granulowas administered subcutaneously at a dosage of 5 g/kg.
cyte, erythroid, megakaryocyte and macrophage (CFUIn the second group, leukapheresis started after total leuko-GEMM) using an inverted microscope. The mean number cytes increased to Ͼ1000 ϫ 10 6 /l and platelets to of colonies per 10 5 nucleated cells was determined. This Ͼ50 ϫ 10 9 /l. The decision to use G-CSF mobilization proportion was related to the cell count of peripheral blood alone or post-chemotherapy was based on clinical considerand PBSC samples. ations. Leukapheresis was performed via a dual lumen hemodialysis/pheresis catheter using a COBE Spectra (COBE BCT, Lakewood, CO, USA) or a Haemonetics V50
Conditioning regimens and supportive care (Haemonetics Corporation, Braintree, MA, USA) cell sepConditioning for transplantation was given according to arator. For the Spectra, a minimum of 10 l of the patient's one of the following regimens: cyclophosphamide 200 blood volume was processed during each procedure. A mg/kg and 1440 cGy total body irradiation for non-Hodgstandard procedure employing 12 passes was used for the kin's lymphoma and Hodgkin's disease; cyclophosphamide V50. 17 Leukapheresis was performed daily until the target 120 mg/kg and busulfan 16 mg/kg for non-Hodgkin's lymcell dose of 7 × 10 8 MNC per kg was obtained. An aliquot phoma and Hodgkin's disease; cyclophosphamide 6000 from each apheresis product was tested for CD34 + cell conmg/m 2 , thiotepa 500 mg/m 2 and carboplatin 800 mg/m 2 for tent and hematopoietic progenitors. The PBSC were frozen breast carcinoma; and cyclophosphamide 100 mg/kg, etoin 10% dimethylsulfoxide (DMSO) using controlled rate poside 1600 mg/m 2 and carboplatin 1500 mg/m 2 for breast freezing at −1°C/min to −90°C and stored in the liquid carcinoma and ovarian carcinoma. On the day of transplant, phase of liquid nitrogen.
PBSC were thawed rapidly at 37°C and infused in three divided doses 3-4 h apart. G-CSF, 5 g/kg, was adminisFlow cytometry and colony assays tered subcutaneously beginning 24 h later and continued daily until granulocytes recovered to у1000 ϫ 10 6 /l for 3 CD34
+ cell quantitation by flow cytometry was performed consecutive days. Prophylactic antibiotics consisted of cipas previously described. 18 Briefly, samples of PBSC were rofloxacin, fluconazole and vancomycin. Cellular blood washed in PBS, centrifuged and counted. The samples were products were leukocyte depleted and irradiated with 2500 incubated for 60 min at room temperature with a phycocGy. Platelets were transfused prophylactically if the plateerythrin (PE)-labeled monoclonal antibody cocktail with let count decreased to less than 20 ϫ 10 9 /l. specificity against CD3 (T cells), CD11b (neutrophils), CD14 (monocytes), and CD19 (B cells) ( WBC Ͻ4000 ϫ 10 6 /l and/or platelets Ͻ150 ϫ 10 9 /l) unrepatients; five patients received a total of six platelet transfusions for non-bleeding thrombocytopenia. A median of lated to recent chemotherapy.
There were nine patients who received G-CSF alone and five leukapheresis procedures (range [3] [4] [5] [6] [7] [8] [9] [10] [11] BFU-E, and 7.2 (0.1-a single agent (two patients), cisplatin in conjunction with other agents (six patients), DHAP (dexamethasone, high-75.0) ϫ 10 4 CFU-GEMM. dose Ara-C and cis-platin) (two patients) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) (one Engraftment kinetics patient). G-CSF was administered for 5 days prior to leukapheresis in the group receiving G-CSF alone; it was Following stem cell infusion and daily administration of G-CSF, recovery to у500 ϫ 10 6 granulocytes/l occurred at a administered a median of 13 days prior to leukapheresis in the group treated with chemotherapy. median of 10 days (range 8-14); platelet recovery to у20 ϫ 10 9 /l was 12 days (range 8-345+) and 14.5 days (range 9-345+) to у50 ϫ 10 9 /l; recovery to a 1% reticuloLeukapheresis cyte occurred at 13.5 days (range 10-84). While all patients showed complete neutrophil engraftment by day 14, four Using the COBE Spectra cell separator, a median of 11 l of the patient's blood volume was processed; 7 l was propatients (15%) remained thrombocytopenic and platelettransfusion dependent for prolonged periods. One patient cessed when the Haemonetics V50 was used. The G-CSF regimen and leukapheresis were well tolerated. Hematoof this group developed relapsed lymphoma in the bone marrow by day +29 and subsequently died on day +59. A logic sequellae included anemia and thrombocytopenia treated with packed red blood cell transfusions in six second patient showed trilineage engraftment on day 14 on /l without transfusion as of day +842. Two additional patients who remained persistently thrombocytopenic showed hypocellularity and amegakaryocytosis on bone marrow biopsy post-transplantation. The four patients without adequate platelet engraftment had NHL and received either busulfan/cytoxan or cytoxan/TBI as the conditioning therapy. In comparison to the 13 other patients (10 NHL, three Hodgkin's) in this study receiving the same preparative regimen, the only significant difference observed was the presence of pre-transplant cytopenia in three of the four persistently thrombocytopenic patients vs one of 13 with adequate platelet recovery (P = 0.02). Differences which did not reach statistical significance were also noted in a lesser total number of CD34 + cells collected (however, this measurement was only obtained in two of the four with failed platelet recovery), and a tendency towards increased prior chemotherapy in the persistently thrombocytopenic patients (median 3.3 regimens vs 2.4). Biopsy evidence of malignancy involving the bone marrow was not found to be a risk factor for non-engraftment of platelets (three of four vs seven of 12, P = NS).
Stem cell dose in relation to early engraftment
Although the target for collection was the total number of mononuclear cells, there was no correlation between this value and the rapidity of either granulocyte or platelet engraftment (r = 0.29 and 0.24, respectively). Assays of hematopoietic colonies and quantitation of CD34 + cells were performed on the last 17 patients in the study, then examined retrospectively in relation to parameters of engraftment. A significant correlation between the total number of CD34 + cells administered and time to granulocyte (r = 0.59, P = 0.004) and platelet (r = 0.58, P = 0.021) recovery was observed (Figure 1) . A correlation was also found between CFU-GM and granulocyte and platelet recovery, as well as between CFU-GM and CD34 + cell a low total dose of CD34 + cells. The relationship between stem cell dose and other outcome variables are presented in Table 2 . For this analysis, we selected a cutoff value of The median hemoglobin level for those in the high CD34 + cell group (n = 8) was 124 g/l (range 114-133) vs 88 g/l 5 ϫ 10 6 CD34 + cells/kg. Patients transplanted using a cell dose greater than this threshold were found to have a mod-(range 74-100) for the low CD34 + cell group (n = 4) (P = 0.004); median platelet count was 202 ϫ 10 9 /l (range 100-est but statistically significant increase by 1 day in the rate of neutrophil recovery to у500 ϫ 10 6 /l. The most striking 278 ϫ 10 9 /l) vs 25 ϫ 10 9 /l (range 16-36 ϫ 10 9 /l) (P = 0.004); median total WBC was 4700 ϫ 10 6 /l (range 4200-difference was in platelet recovery: 9 vs 21 days until platelet recovery to у20 ϫ 10 9 /l, and 10.5 vs 26 days to a stable 13 900 ϫ 10 6 /l) vs 2500 ϫ 10 6 /l (range 900-6200 ϫ 10 6 /l) (P = 0.10); median neutrophil count was 3100 ϫ 10 6 /l platelet count of у50 ϫ 10 9 /l. The earlier recovery resulted in significantly fewer platelet transfusions in the group of (range 2500-11 500 ϫ 10 6 /l) vs 1400 ϫ 10 6 /l (range 200-4300 ϫ 10 6 /l) (P = 0.15). The 12 patients included in this patients infused with the higher dose of stem cells.
analysis were those in remission and who had blood count Stem cell dose in relation to subsequent hematologic data available at 180 days. Of the remaining five, two had function expired, two had relapsed, and one was lost to follow-up. Hematologic values at a stable baseline 4-8 weeks prior to The effect of high and low stem cell dose on hematopoietic reconstitution was also evident at 180 days after transplant.
initiating therapy tended to be greater in the high CD34 employing G-CSF with/without chemotherapy, and the use of different endpoints of stem cell collection, the range of lowest (0.5-4.3 × 10 6 /kg) and median (4.7-11.6 × 10 6 /kg) yields of CD34 + cells in several current studies are convergent. 11, 22, 23 The reported median range of engraftment paragroup (median hemoglobin 137 g/l vs 128 g/l; platelets 238 ϫ 10 9 /l vs 195 ϫ 10 9 /l), however, these differences meters for neutrophils (9-12.7 days) and for platelets (9-14 days) are also similar. 11, 13, 22, 23 were not statistically significant using the Mann-Whitney test. Analysis using Spearman statistics demonstrated a corConsistent with other studies, the major benefit seen in patients infused with the higher stem cell dose was rapid relation between CD34
+ cell yield and baseline hemoglobin (r = 0.53; P = 0.04), but not with baseline WBC, neutroand sustained platelet recovery and the avoidance of prolonged platelet transfusion dependence. 5 Short-term as well phils, or platelet count. In addition, no relationship was found between baseline hematologic parameters and early as long-term effects on megakaryocytopoiesis have been observed using stem cell support from peripheral blood. A engraftment or later hematologic indices, with the exception of baseline and day 180 platelet count (r = 0.63, P temporary decrease in platelet count occurring 3-6 weeks after initial engraftment was seen in one patient in our = 0.04). Figure 2 extends the correlation of CD34 + cells with study, and has been reported in several others. 15, 24 This decrement has not been found to correlate with progenitor cell hemoglobin and platelet levels in patients surviving to 360 and 540 days post-transplantation, censored for relapse. dose or to presage graft failure. Although the mechanism is uncertain, it could be related to a relative lack of more While the degree of erythroid and platelet recovery generally corresponded to the dose of infused stem cells, we did committed precursors occurring before less committed precursors have reached a sufficient proliferative level. 15 A not observe such a long-term relationship with either neutrophil or total WBC levels (data not shown). more significant clinical problem is the lack of sustained platelet engraftment, which was observed in 15% of this patient cohort. Although not reported in recipients of comDurability of engraftment bined marrow/peripheral blood stem cells, the frequency of delayed or suboptimal platelet engraftment in autologous The median duration of follow-up as of 31 December 1994 was 602 days (49-914) for the entire group of patients. At marrow stem cell transplantation ranges from 5-22%. [24] [25] [26] Using unmobilized peripheral blood stem cells, Kessinger 180 days, 20 patients (10 lymphoma, nine breast carcinoma, one Hodgkin's disease) were in remission and evaluable for et al 27 found delayed platelet recovery (Ͼ100 days to a platelet count of у20 ϫ 10 9 /l) in 3/31 (10%) of evaluable assessment of the quality of hematopoietic reconstitution; at 360 days, 10 patients (four lymphoma, five breast carcipatients. Four other studies which employed GM-CSF ± chemotherapy mobilization reported platelet engraftment noma, one Hodgkin's); and, at 540 days, eight patients (three lymphoma, four breast carcinoma, one Hodgkin's).
failure rates of 8-21% of patients. 7, 14, 28, 29 Several observations support the important effect of stem The median follow-up of this longest-surviving group is 680 days (596-914), without indication of any loss of hemcell dose on delayed platelet recovery. In this study, the patient with the lowest measured level of CD34 + cells atopoietic function to date. This includes the two patients who remained persistently thrombocytopenic after trans-(0.6 ϫ 10 6 /kg) remained platelet dependent following transplant. Siena et al 2 reported that their patient infused with plantation, who had received the lowest doses of CD34 vered to a platelet count of only 30 ϫ 10 9 /l by day +60. While the correlation between CD34 + cell dose and rapid hematopoietic recovery is well-established, its apparent Bensinger et al 11 noted delayed platelet engraftment (49 days to reach 20 ϫ 10 9 /l) in one of 11 patients. This patient influence on later hematologic functioning has not previously been noted. We observed a steady rise in hemoglohad received an infusion dose of 1.6 ϫ 10 6 CD34 + cells/kg and 2.4 ϫ 10 4 CFU-GM/kg, the lowest levels measured in bin levels and platelets at the later time-points analyzed following transplant. Recovery of hemoglobin reached a the patients evaluable for platelet recovery. More recently, Haas et al 30 also found that platelet recovery was substanplateau by day +360, whereas platelet recovery continued to day +540. Although these trends were noted in both high tially delayed in patients receiving less than 2.5 ϫ 10 6
CD34
+ cells/kg. Although platelet non-engraftment was not and low CD34 groups, they were more pronounced in the former. We interpret these observations to indicate that the reported, the longest time to reach a count of 20 ϫ 10 9 /l was seen in the patient transplanted with the lowest stem CD34 + cell dose contributes to the overall quality of hematopoietic reconstitution, both early and late. However, since cell dose: 0.03 ϫ 10 6 CD34 + cells/kg. Another factor postulated to influence platelet disease relapse and/or death reduced the number of evaluable patients at each time-point post-transplant, additional engraftment is the status of the marrow microenvironment itself, either because of inadequate mobilization of stem studies will be needed to to confirm this finding. The present study summarizes the results of an early cells or inhibition of engraftment of those megakaryocyte precursors which migrate there after infusion. Our study PBSC protocol employed at our institution, in which only 60% of patients reached the optimum collection threshold indicates that patients with marrow dysfunction as evidenced by pre-existing, stable cytopenia are particularly at of 5 ϫ 10 6 CD34 + cells/kg. The group which exceeded this value did so easily, requiring an average of only two leurisk for slow (or no) platelet engraftment. Of the five cytopenic patients treated, three failed to recover self-sustaining kapheresis procedures. 32 By contrast, for patients who did not reach the 5 ϫ 10 6 threshold, it can be estimated (by platelet levels (ie у20 ϫ 10 9 /l), and the other two had delayed recovery at 21 and 28 days. Whether this was due determining the average yield per collection) that 16 or more leukapheresis procedures would have been needed to to the lower harvest of stem cells obtained from these patients or other factors associated with marrow stromal provide sufficient cells for optimal hematopoietic reconstitution. A wide inter-patient variability in mobilization dysfunction could not be determined. However, the influence of the hematopoietic microenvironment is suggested potential has been noted previously. 12,14 Administration of a higher dose of G-CSF, 33 the use of chemotherapy having in the recent study by Weaver et al, 31 who noted that platelet recovery took longer in patients requiring two mobiliza greater myelosuppressive effect, 34 or using newer recombinant hematopoietic growth factors can be expected to ation series vs one to reach the same target collection threshold of 2.5 ϫ 10 6 CD34 + cells/kg. improve stem cell yields. 35 However, the association of 
